High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis

Journal of Clinical Oncology

Volumn 29, Issue 25, 2011, Pages 3466-3473

  Moore, Russell A ^a   Adel, Nelly ^a   Riedel, Elyn ^a   Bhutani, Manisha ^b   Feldman, Darren R ^a   Tabbara, Nour Elise ^a   Soff, Gerald ^a   Parameswaran, Rekha ^a   Hassoun, Hani ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTICOAGULANT AGENT; BEVACIZUMAB; CISPLATIN; ETOPOSIDE; GEMCITABINE; HEMOGLOBIN; IRINOTECAN; PACLITAXEL; PEMETREXED; TEMOZOLOMIDE; VINBLASTINE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTERY EMBOLISM; ARTERY THROMBOSIS; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CENTRAL VENOUS CATHETER; CONFERENCE PAPER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052751246     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.5669     Document Type: Conference Paper

References (44)

1. Silverstein MD, Heit JA, Mohr DN, et al: Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 158:585-593, 1998 (Pubitemid 28144815)
2. Lee AY, Levine MN: Venous thromboembolism and cancer: Risks and outcomes. Circulation 107:I17-21, 2003 (suppl 1)
3. Heit JA, Silverstein MD, Mohr DN, et al: Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 160:809-815, 2000 (Pubitemid 30165241)
4. Khorana AA, Francis CW, Culakova E, et al: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632-634, 2007 (Pubitemid 46680709)
5. Chew HK, Wun T, Harvey D, et al: Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458-464, 2006
6. Sørensen HT, Mellemkjaer L, Olsen JH, et al: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846-1850, 2000 (Pubitemid 32104130)
7. Lyman GH, Khorana AA: Cancer, clots and consensus: New understanding of an old problem. J Clin Oncol 27:4821-4826, 2009
8. Clahsen PC, Van de Velde CJ, Julien JP, et al: Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 12:1266-1271, 1994 (Pubitemid 24173943)
9. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989 (Pubitemid 19062522)
10. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682, 1997 (Pubitemid 27508191)
11. Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005-1018, 1990 (Pubitemid 20200188)
12. Levine MN, Gent M, Hirsh J, et al: The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318:404-407, 1988 (Pubitemid 18044179)
13. Pritchard KI, Paterson AH, Paul NA, et al: Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer: National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 14:2731-2737, 1996 (Pubitemid 26329659)
14. Rivkin SE, Green S, Metch B, et al: Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study. J Clin Oncol 12:2078-2085, 1994 (Pubitemid 24356024)
15. Saphner T, Tormey DC, Gray R: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9:286-294, 1991
16. Azak A, Oksüzoǧlu B, Deren T, et al: Cerebrovascular accident during cisplatin-based combination chemotherapy of testicular germ cell tumor: An unusual case report. Anticancer Drugs 19:97-98, 2008 (Pubitemid 350190973)
17. Doll DC, Ringenberg QS, Yarbro JW: Vascular toxicity associated with antineoplastic agents. J Clin Oncol 4:1405-1417, 1986 (Pubitemid 16028036)
18. Gerl A: Vascular toxicity associated with chemotherapy for testicular cancer. Anticancer Drugs 5:607-614, 1994
19. Grenader T, Shavit L, Ospovat I, et al: Aortic occlusion in patients treated with cisplatin-based chemotherapy. Mt Sinai J Med 73:810-812, 2006 (Pubitemid 44445786)
20. Içli F, Karaoǧuz H, Dinçol D, et al: Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 72:587-593, 1993 (Pubitemid 23193472)
21. Illarramendi JJ, Gallego J: Cisplatin-based chemotherapy and acute cerebrovascular events. Lancet 338:705, 1991
22. Jafri M, Protheroe A: Cisplatin-associated thrombosis. Anticancer Drugs 19:927-929, 2008
23. Lechner D, Kollars M, Gleiss A, et al: Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost 5:2445-2452, 2007 (Pubitemid 350154355)
24. Pretnar-Oblak J, Zaletel M, Jagodic M, et al: Thrombosis of internal carotid artery after cisplatin-based chemotherapy. Eur Neurol 57:109-110, 2007
25. Karam C, Koussa S: Cerebral dural sinus thrombosis following cisplatin chemotherapy. J Clin Neurosci 15:1274-1275, 2008
26. Czaykowski PM, Moore MJ, Tannock IF: High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol 160:2021-2024, 1998 (Pubitemid 128703605)
27. Weijl NI, Rutten MF, Zwinderman AH, et al: Thromboembolic events during chemotherapy for germ cell cancer: A cohort study and review of the literature. J Clin Oncol 18:2169-2178, 2000 (Pubitemid 30324370)
28. Numico G, Garrone O, Dongiovanni V, et al: Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 103:994-999, 2005 (Pubitemid 40270076)
29. Al-Batran SE, Hartmann JT, Probst S, et al: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435-1442, 2008
30. Starling N, Rao S, Cunningham D, et al: Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: A report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 27:3786-3793, 2009
31. Khorana AA, Kuderer NM, Culakova E, et al: Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902-4907, 2008
32. Behrendt CE, Ruiz RB: Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thromb Haemost 90:734-737, 2003 (Pubitemid 37287643)
33. Fotopoulou C, DuBois A, Karavas AN, et al: Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel- containing first-line chemotherapy: An exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol 26:2683-2689, 2008
34. Anders JC, Grigsby PW, Singh AK: Cisplatin chemotherapy (without erythropoietin) and risk of life-threatening thromboembolic events in carcinoma of the uterine cervix: The tip of the iceberg? A review of the literature. Radiat Oncol 1:14, 2006
35. Lyman GH, Khorana AA, Falanga A, et al: American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505, 2007 (Pubitemid 350232226)
36. Couban S, Goodyear M, Burnell M, et al: Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23:4063-4069, 2005 (Pubitemid 46211311)
37. Haas SK, Kakkar A, Kemkes-Matthes B, et al: Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer: Results of the TOPIC studies. J Thromb Haemost 3, 2005 (suppl 1; abstr OR059)
38. Levine M, Hirsh J, Gent M, et al: Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886-889, 1994 (Pubitemid 24113632)
39. Perry JR, Rogers L, Laperriere N, et al: PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. J Clin Oncol 25:77s, 2007 (suppl; abstr 2011)
40. Young AM, Billingham LJ, Begum G, et al: Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): An open-label randomised trial. Lancet 373:567-574, 2009
41. Riess H, Pelzer U, Hilbig A, et al: Rationale and design of PROSPECT-CONKO 004: A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy. BMC Cancer 8:361, 2008
42. Riess H, Pelzer U, Opitz B, et al: A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. J Clin Oncol 28:309s, 2010 (suppl; abstr 4033)
43. Maraveyas A, Waters J, Roy R, et al: Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): A multicentre, randomised phase IIB trial (the UK FRAGEM study). Eur J Cancer Supplements 7:362, 2009 (abstr 6503)
44. Agnelli G, Gussoni G, Bianchini C, et al: Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study. Lancet Oncol 10:943-949, 2009